• ScreenPro Security (SCRN) has announced a non-brokered private placement financing for gross proceeds of up to $1,000,000
  • The company will issue up to 20 million units for $0.05 per unit
  • The gross proceeds will be used for general working capital
  • The offering is expected to close on or about November 17, 2022
  • ScreenPro is a medical technology company
  • ScreenPro (SCRN) opened trading at C$0.025

ScreenPro Security (SCRN) has announced a non-brokered private placement financing for gross proceeds of up to $1,000,000.

The company will issue up to 20 million units for $0.05 per unit. Each unit will consist of one common share and one share purchase warrant. Each warrant will entitle the holder to acquire one additional share for a period of eighteen months.

The gross proceeds will be used for general working capital, growth, expansion, and general corporate purposes.

ScreenPro may pay a cash finders’ fee.

The offering is expected to close on or about November 17, 2022.

All securities issued will be subject to a statutory four-month hold period.

ScreenPro is a medical technology company that provides turnkey screening solutions with its proprietary medical alerting software. ScreenPro also recently introduced Naturevan Nutrition Ltd. to its portfolio, providing vitamins and supplements that are made in Canada and distributed for sale online.

ScreenPro (SCRN) opened trading at C$0.025.


More From The Market Online

Westinghouse Electric files for US IPO

Westinghouse Electric Company, jointly owned by Cameco and Brookfield Renewable Partners, confidentially filed for a US IPO.

The 5-Minute Investor Podcast, Ep. 72: The next AI gold rush is copper

Check out ep. 72 of The 5-Minute Investor Podcast, with analysis on copper stocks Freeport-McMoRan and Capstone Copper.

Buzz on the Bullboards: Contracts, cashflows, and delistings

Uncertainty around Iran has weighed on sentiment, reminding investors that even strong stories can be overshadowed by geopolitical risk.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.